CG Oncology (CGON)
Developing cretostimogene for bladder cancer alongside contract fill-and-finish manufacturing.
$78.47
vs last close+0.22 (+0.28%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 106.57% | 94.46M shares | |
|---|---|---|---|
| 246 holders · as of Jun 30, 2026 | |||
| Insiders | 4.19% | 3.72M shares | |
| 2 holders · as of Mar 13, 2026 | |||
| Strategic holders | 16.26% | 14.41M shares | |
| 3 holders · as of Feb 14, 2025 | |||
| Adds to | 127.02% | ||
88.64M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 127.02%; nothing is left for Other.
13F, as of Jun 30, 2026
246 holders · 94.46M shares · 39 new positions · 133 increased · 76 reduced · 38 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| RTW Investments, LP | 8.51M | 9.61% | +1.53M | Aug 14, 2026 |
| T. Rowe Price Investment Management, Inc. | 6.62M | 7.46% | −103.5K | Aug 14, 2026 |
| Decheng Capital LLC | 6.37M | 7.19% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 6.26M | 7.06% | +1.19M | Aug 7, 2026 |
| Wellington Management Group LLP | 5.32M | 6.01% | −46.5K | Aug 14, 2026 |
| FMR LLC | 4.16M | 4.69% | +396.6K | Aug 13, 2026 |
| Price T Rowe Associates Inc /MD/ | 3.81M | 4.29% | +152.0K | Aug 14, 2026 |
| TCG Crossover Management, LLC | 3.67M | 4.14% | 0 | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| RTW Investments, LP | 8.30% | 6.98M | 13G | May 15, 2026 |
| T. Rowe Price Investment Management, Inc. | 8.00% | 6.72M | 13G | May 15, 2026 |
| Wellington Management Group LLP | 7.20% | 5.51M | 13G | Nov 12, 2025 |
| Decheng Capital Global Life Sciences Fund IV, L.P. | 7.00% | 5.32M | 13G | Feb 14, 2025 |
| Juliet Tammenoms Bakkerincl. Patrick G. Enright, Longitude Prime Fund, L.P. +3 more | 6.00% | 4.66M | 13D | Sep 18, 2025 |
| BlackRock, Inc. | 5.30% | 3.57M | Nov 8, 2024 | |
| FMR LLC | 5.10% | 3.86M | 13G | Aug 6, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 15, 2026 | Leonard E. Postdirector | Sale | 1,000 | $72.98 | 0 |
| Aug 14, 2026 | Leonard E. Postdirector | Sale | 1,000 | $74.54 | 0 |
| Jul 15, 2026 | Leonard E. Postdirector | Sale | 1,000 | $71.17 | 0 |
| Jul 10, 2026 | James Mulaydirector | Sale | 24,165 | $75.16 | 0 |
| Jun 25, 2026 | Brian Guan-Chyun Liudirector | Purchase | 371,085 | $66.87 | 1,886,236 |
| Jun 24, 2026 | Leonard E. Postdirector | Sale | 5,000 | $70.00 | 0 |
| Jun 22, 2026 | Leonard E. Postdirector | Sale | 5,000 | $65.00 | 0 |
| Jun 15, 2026 | James Mulaydirector | Sale | 1,310 | $60.12 | 0 |
| Jun 4, 2026 | Leonard E. Postdirector | Sale | 1,000 | $54.50 | 0 |
| Apr 17, 2026 | James Mulaydirector | Sale | 15,600 | $73.01 | 0 |
House and Senate disclosures
Not reported.